PMA device
Sapien 3 Transcatheter Heart Valve and Accessories
Edwards Lifesciences, LLC · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Jun 17, 2015, newest Oct 10, 2025Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
19
PMA pathway
Device trials
51
Naming "Sapien 3"
MAUDE reports
24,850
Brand "Sapien 3", since 2015
PubMed studies
1,126
Mentioning "Sapien 3"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sapien 3 Transcatheter Heart Valve and Accessories
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 19 decisions filed under this name.
- SAPIEN 3 TRANSCATHETER HEART VALVE AND ACCESSORIESPMA supplement
P140031-S194 · Decided Oct 10, 2025 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
- Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systemPMA supplement
P140031-S182 · Decided Apr 30, 2025 · 166 days after receipt · Panel Track
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
P140031-S130 · Decided Sep 17, 2021 · 73 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
3 more FDA decisions with a free account
Older decisions: P140031-S107, P140031-S087, P140031-S067, P140031-S064, P140031-S052, P140031-S048, P140031-S047, P140031-S028, P140031-S015, P140031-S010, P140031-S003, P140031-S002, P140031
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Sapien 3", any status and sponsor, newest update first.
- ALTERRA: SAPIEN 3 THV With the Alterra Adaptive PrestentActive, not recruiting
Edwards LifesciencesPublic (EW)
NCT03130777 · 86 participants · Start Aug 22, 2017 · Primary completion Jul 14, 2022
Device: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV · For: Pulmonary Disease; Transcatheter Pulmonary Valve Replacement (TPVR); Tetralogy of Fallot and 2 more
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 14 sites in all
- Balloon vs. Self Expanding Transcatheter Valve for Degenerated BioprosthesisPivotal-lookingRecruiting
Erasmus Medical CenterAcademic, hospital or other
NCT04843072 · 600 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2028
Device: EVOLUT R/PRO/PRO+/FX bioprosthesis; Edwards Sapien S3/Ultra bioprosthesis and 1 more · For: Valve Heart Disease
Sites: Los Angeles, California; Vienna, Austria; Vancouver, Canada · 14 sites in all
- ALTERRA Post-Approval StudyActive, not recruiting
Edwards LifesciencesPublic (EW)
NCT05378386 · 150 participants · Start May 12, 2022 · Primary completion Sep 25, 2025
Device: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System · For: Pulmonary Valve Insufficiency; Complex Congenital Heart Defect; Tetralogy of Fallot and 2 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 24 sites in all
48 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sapien 3", and for the whole product code for context.
This brand
24,850 reports: 1,170 malfunction, 21,270 injury, 2,409 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
2015691-2026-19854 · Received Oct 30, 2026 · Event dated Sep 30, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Calcified
Patient problem as coded: Chest Pain; Dyspnea
2015691-2026-19877 · Received Oct 30, 2026 · Event dated Sep 29, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
2015691-2026-19833 · Received Oct 29, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0835-2019 · Started Jan 22, 2019
Reason given: This action has been initiated to address complaint reports received for crimp balloon and inflation balloon component separation during TAVR procedures.
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-2435-2018 · Started Jun 11, 2018
Reason given: SAPIEN 3 THV was packaged with the incorrect valve size with respect to the label.
Cause as FDA categorized it: Labeling False and Misleading · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-0293-2018 · Started Jul 21, 2017 · Posted by FDA Jan 10, 2018
Reason given: A component in the Certitude Loader may have a molding overflow defect that could detach during advancement of the delivery system and potentially embolize from the loader into the patient.
Cause as FDA categorized it: Employee error · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Published research
The most relevant PubMed records for "Sapien 3"[tiab]. The summary above synthesizes these.
- SAPIEN 3 Ultra Resilia: Critical Reflections on Real-World Performance.
Amat-Santos IJ, García-Gómez M · JACC Cardiovasc Interv · 2024Editorial, Comment
- Outcomes of transcatheter pulmonary SAPIEN 3 valve implantation: an international registry.
Hascoët S, Bentham JR, Giugno L, et al. · Eur Heart J · 2024Observational Study, Research Support, Non-U.S. Gov't
- Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients.
Madhavan MV, Kodali SK, Thourani VH, et al. · J Am Coll Cardiol · 2023Randomized Controlled Trial
- SAPIEN 3 in type 0 bicuspid aortic valves: Promising early results.
Alperi A, Avanzas P · Int J Cardiol · 2025Editorial
- Sapien 3: A Triple Threat to Aortic Stenosis.
Kar S, Sharma R · JACC Cardiovasc Interv · 2015Editorial, Comment
- Successful SAPIEN 3 Implantation for Structural Valve Deterioration of a SAPIEN XT.
Imaoka T, Naganuma T, Nakamura S · Circ J · 2023
- Valve Wars: Sapien vs Evolut Transcatheter Valves, Whac-a-Mole Edition.
Jacquemyn X, Sultan I · Can J Cardiol · 2025Editorial
- SAPIEN 3 Ultra Transcatheter Aortic Valve Device: Two Sides of the Moon.
Barbanti M, Costa G · JACC Cardiovasc Interv · 2020Editorial, Comment
- ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation.
Pellegrini C, Rheude T, Renker M, et al. · EuroIntervention · 2023
- Performance and outcomes of the SAPIEN 3 Ultra RESILIA transcatheter heart valve in the OCEAN-TAVI registry.
Yamamoto M, Yashima F, Shirai S, et al. · EuroIntervention · 2024
- Multicenter Pivotal Study of the Alterra Adaptive Prestent for the Treatment of Pulmonary Regurgitation.
Dimas VV, Babaliaros V, Kim D, et al. · JACC Cardiovasc Interv · 2024Multicenter Study, Clinical Trial
- Use of the SAPIEN 3 Transcatheter Heart Valve in High-Risk Scenarios.
Nascimbene A, McAlister C, Yo D, et al. · Tex Heart Inst J · 2022
Other devices of this type
Also filed under product code NPT.
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
- LOTUS Edge Valve SystemBoston Scientific Corporation · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.